Industry
Biotechnology
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Loading...
Open
1.38
Mkt cap
120M
Volume
279K
High
1.45
P/E Ratio
-0.57
52-wk high
3.41
Low
1.32
Div yield
N/A
52-wk low
0.54
Portfolio Pulse from Benzinga Newsdesk
July 18, 2024 | 1:15 pm
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 4:01 pm
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 8:02 pm
Portfolio Pulse from Benzinga Newsdesk
June 20, 2024 | 5:20 pm
Portfolio Pulse from Benzinga Newsdesk
May 28, 2024 | 11:06 am
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 8:54 pm
Portfolio Pulse from Benzinga Insights
May 01, 2024 | 8:31 pm
Portfolio Pulse from Happy Mohamed
March 14, 2024 | 8:05 pm
Portfolio Pulse from Benzinga Newsdesk
February 26, 2024 | 12:18 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.